PTEN Hamartoma-Tumour Syndrome: a model for the practice of clinical cancer genetics

Published on September 3, 2014   21 min

Other Talks in the Series: Molecular Genetics of Human Disease

0:00
I'm Professor Charis Eng, the Hardis chairperson of the Genomic Medicine Institute and director at the Center for Personalized Genetic Healthcare at the Cleveland Clinic. I shall be speaking to you about the PTEN Hamartoma-tumour Syndrome as a model for the practice of clinical cancer genetics.
0:21
When we practice clinical cancer genetics, we ask ourselves when faced with a patient with cancer, is it heritable or is it sporadic?, because this has implications for the patient. For example, which cancers will this patient be at risk for? At what ages do these risks arise? What does one do for the patient? In addition to the patient, what are implications for the patient's family? Who amongst them is at risk for cancer, and what does one do for each family member at risk?
0:56
Clinical clues suggesting heritable cancer include young age of onset, bilateral disease in paired organs, multifocal tumors, association with other tumor types-- for example, breast and ovarian cancer, colon and endometrial cancers. Familial clustering of cancers, but not always.
Hide

PTEN Hamartoma-Tumour Syndrome: a model for the practice of clinical cancer genetics

Embed in course/own notes